European Association of Nuclear Medicine - EANM

05/02/2026

🧠 𝗘𝗔𝗡𝗠 #𝗙𝗼𝗰𝘂𝘀𝗠𝗲𝗲𝘁𝗶𝗻𝗴𝟳 – 𝗗𝗮𝘆 𝟭 𝗞𝗶𝗰𝗸𝗼𝗳𝗳!

Over the next two and a half days, we will explore how advanced imaging and biomarkers are transforming 's disease management — from enabling earlier and more accurate diagnosis to supporting treatment selection and monitoring therapeutic response.

We warmly welcome all participants and look forward to insightful discussions, knowledge exchange, and fruitful collaboration throughout the meeting.🤝

03/02/2026

📢 𝗪𝗲’𝗿𝗲 𝗸𝗶𝗰𝗸𝗶𝗻𝗴 𝗼𝗳𝗳 𝗼𝘂𝗿 𝗹𝗶𝘃𝗲 𝘄𝗲𝗯𝗶𝗻𝗮𝗿 𝘀𝗲𝗿𝗶𝗲𝘀 𝗼𝗳 𝟮𝟬𝟮𝟲 𝘄𝗶𝘁𝗵 "𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻𝘀 𝗶𝗻 𝗧𝗵𝗲𝗿𝗮𝗻𝗼𝘀𝘁𝗶𝗰𝘀 𝗳𝗼𝗿 𝗡𝗲𝘂𝗿𝗼𝗯𝗹𝗮𝘀𝘁𝗼𝗺𝗮", 𝘁𝗮𝗸𝗶𝗻𝗴 𝗽𝗹𝗮𝗰𝗲 𝘁𝗵𝗶𝘀 𝗙𝗿𝗶𝗱𝗮𝘆!

📅 𝗗𝗮𝘁𝗲: February 6, 2026
🕐 𝗧𝗶𝗺𝗲: 13:30 CET
🎟️ 𝗥𝗲𝗴𝗶𝘀𝘁𝗿𝗮𝘁𝗶𝗼𝗻: FREE
🔗 𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 𝗵𝗲𝗿𝗲: https://elearning.eanm.org/course/live-webinar-innovations-in-theranostics-for-neuroblastoma-february-6-2026

This live webinar will provide a comprehensive update on instrumental and radiopharmaceutical innovations in the diagnosis and treatment of neuroblastoma. Participants will explore current and emerging imaging modalities, with a comparative analysis of MIBG, MFBF, FDOPA, and Gallium-based tracers, highlighting their evolving roles in staging, risk stratification, and response assessment.

Furthermore, the webinar will address recent changes in clinical practice and the challenges these advancements pose for pediatric oncologists and nuclear medicine physicians, emphasizing multidisciplinary decision-making.

In addition, the programme will review novel therapeutic strategies for refractory and relapsed neuroblastoma, with a focus on radioligand therapy and its integration with immunotherapy approaches, including CAR-T cell therapy. Through state-of-the-art updates and clinical perspectives, the course aims to equip clinicians with practical insights for optimizing diagnostic accuracy and therapeutic outcomes in this complex pediatric malignancy.

🎓 𝗟𝗲𝗮𝗿𝗻𝗶𝗻𝗴 𝗼𝗯𝗷𝗲𝗰𝘁𝗶𝘃𝗲𝘀:
• Describe recent instrumental and radiopharmaceutical innovations in the diagnosis and management of neuroblastoma
• Compare the clinical indications, advantages, and limitations of MIBG, MFBF, FDOPA, and Gallium-based imaging tracers in neuroblastoma
• Evaluate how emerging imaging techniques are changing staging, risk stratification, and treatment response assessment in pediatric patients
• Identify current challenges and unmet needs faced by pediatric oncologists and nuclear medicine physicians
• Discuss the principles and clinical applications of radioligand therapy in refractory and relapsed neuroblastoma
• Assess the potential role of combined treatment strategies in improving patient outcomes

👥 𝗧𝗮𝗿𝗴𝗲𝘁 𝗔𝘂𝗱𝗶𝗲𝗻𝗰𝗲:
Nuclear medicine physicians

🎙️ 𝗠𝗼𝗱𝗲𝗿𝗮𝘁𝗼𝗿:
Marie Luporsi

👥 𝗦𝗽𝗲𝗮𝗸𝗲𝗿𝘀:
Julian Rogasch
Bart de Keizer

Don’t miss out on this chance to !

📱 Now also on the go with the 𝗘𝗦𝗠𝗜𝗧 𝗤𝘂𝗶𝘇𝗨𝗽 𝗔𝗽𝗽!
🔗 Get the new 𝗘𝗦𝗠𝗜𝗧 𝗤𝘂𝗶𝘇𝗨𝗽 𝗔𝗽𝗽 here: https://lnkd.in/d3BjHuAm

03/02/2026

The Technologists Benchmark Document (EQF Level 7 – Master’s level) supports the continued professional development of Nuclear Medicine Technologists.

Developed by the EANM Technologists Committee with the support of international partner societies, the Canadian Association of Medical Radiation, the Australian & New Zealand Society of Nuclear Medicine and the EFRS - European Federation of Radiographer Societies 🤝

🔗 Access it here: https://eanm.org/education/trainings-certifications/technologists-benchmark-documents-eqf/

29/01/2026

🎓 𝗝𝗼𝗶𝗻 𝘂𝘀 𝗶𝗻 𝗩𝗶𝗲𝗻𝗻𝗮 𝗳𝗼𝗿 𝘁𝗵𝗲 𝗳𝗶𝗿𝘀𝘁 𝗰𝗼𝘂𝗿𝘀𝗲 𝗼𝗳 𝟮𝟬𝟮𝟲 𝗼𝗻 𝗗𝗼𝘀𝗲-𝗘𝗳𝗳𝗲𝗰𝘁 𝗥𝗲𝘀𝗽𝗼𝗻𝘀𝗲 𝘁𝗼 𝗧𝗮𝗿𝗴𝗲𝘁𝗲𝗱 𝗥𝗮𝗱𝗶𝗼𝗻𝘂𝗰𝗹𝗶𝗱𝗲 𝗧𝗵𝗲𝗿𝗮𝗽𝘆!

📅 𝗗𝗮𝘁𝗲: March 19–20, 2026
📍 𝗟𝗼𝗰𝗮𝘁𝗶𝗼𝗻: Vienna, Austria
🔗𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 𝗵𝗲𝗿𝗲: https://esmit.eanm.org/event/dose-effect-response-to-targeted-radionuclide-therapy/

This intensive 1,5-day course aims to bridge the gap between radiobiology, dosimetry, and clinical practice in targeted radionuclide therapy. Designed for early-career nuclear medicine physicians and medical physicists, the programme explores dose-response relationships in the three most commonly used theranostic molecules: somatostatin-ligands for neuroendocrine tumours, PSMA-inhibitors for prostate cancer, and radioiodine for thyroid malignancies.

Through a balanced faculty of radiobiologists, dosimetry experts, and experienced nuclear medicine physicians, participants will gain practical insights into the biological effects of radiation, dosimetry calculation methodologies, and their clinical implementation. The course emphasizes hands-on learning through joint case sessions, interactive workshops, and patient-specific treatment planning exercises.

🎯 𝗪𝗵𝗼 𝘀𝗵𝗼𝘂𝗹𝗱 𝗮𝘁𝘁𝗲𝗻𝗱?
Early-career nuclear medicine doctors and medical physicists

🎓𝗟𝗲𝗮𝗿𝗻𝗶𝗻𝗴 𝗼𝗯𝗷𝗲𝗰𝘁𝗶𝘃𝗲𝘀:
By the end of the course, participants will be able to:
• Explain the fundamental radiobiological principles underlying dose-effect relationships in targeted radionuclide therapy
• Describe the complete workflow and apply core dosimetry concepts to clinical TRT scenarios
• Compare and contrast the clinical applications, dose-response characteristics, and dosimetric considerations for somatostatin-ligand therapy, PSMA-inhibitor therapy, and radioiodine therapy
• Interpret key clinical trial outcomes and evidence-based data related to dosimetry-guided TRT
• Design a patient-specific TRT treatment plan
• Identify the practical challenges and solutions for implementing dosimetry protocols in routine clinical nuclear medicine practice

🎙️ 𝗙𝗲𝗮𝘁𝘂𝗿𝗲𝗱 𝗦𝗽𝗲𝗮𝗸𝗲𝗿𝘀:
Julie Nonnekens
Lars Tore Gyland Mikalsen
Francesco Cicone
Francesco Giammarille

📚This is your chance to expand your expertise and get to know professionals in the field. Don’t miss out on this opportunity to !

📱 Now also on the go with the 𝗘𝗦𝗠𝗜𝗧 𝗤𝘂𝗶𝘇𝗨𝗽 𝗔𝗽𝗽!
🔗 Get the new 𝗘𝗦𝗠𝗜𝗧 𝗤𝘂𝗶𝘇𝗨𝗽 𝗔𝗽𝗽 here: https://lnkd.in/d3BjHuAm

28/01/2026

Don’t miss your chance to participate in the 2026 EANM Young Investigators Meeting! 🚨

👥 Open to researchers under 33 at the time of application
🚆 Accommodation and travel costs are covered by EANM
⏰ Applications are open until February 9 (23:59 CET)

👉 Apply today: https://eanm.org/congress-scientific-events/young-investigators-meeting/2026-edition/

27/01/2026

Kick off the new year by diving into the latest publications from the EANM journals! 🚨

➡️ The EANM Journal:
• Prospects of PET/MR: the 5th Chinese PET/MR academic symposium
• Systematic analysis of amino acid PET use in Germany: strategic considerations for widespread clinical application
• Brain [18F]FDG-PET databases after the COVID-19 pandemia: Rethinking normality
• E pluribus unum. Interdisciplinary cooperation on issues pertaining to the role of nuclear medicine in the treatment of differentiated thyroid cancer: a commentary on the 2025 American Thyroid Association guidelines
• Endoscopic ultrasonography (EUS)-guided SSTR PET/CT imaging in the management of patients with small (

26/01/2026

Join the 22nd European Symposium on Radiopharmacy and Radiochemistry on April 16-19, 2026, in Bergen 🇳🇴!

Make sure to register before February 14, 2026, to benefit from the early registration fee.

🔗 Find out more: https://www.esrr.info/

22/01/2026

Kick off of the EANM Spring Committee Meetings 🚀

Last week, we started off our series of annual Spring Committee Meetings with the EANM Neuroimaging Committee.

We are looking forward to welcoming all our committees to our Vienna office in the coming weeks for what promises to be insightful and productive meetings!

21/01/2026

The brain PET accreditation programme has levelled up! 🧠

Centres can now apply to have their dedicated brain PET scanners accredited by EARL and connect to a large, quality-proven and harmonised data network.

This EARL accreditation enables:

🔹 Harmonised brain PET data across sites and systems
🔹 Access to the largest global network dedicated to brain PET standardisation
🔹 Improved comparability for multicentre studies
🔹 Accelerated translation from research to clinical impact

We invite sites worldwide to apply and take the next step in advancing high-quality brain PET scanning!

👉 Learn more: https://earl.eanm.org/18f-brain-pet-ct/
👉 Apply here: https://earl.eanm.org/accreditation-enrollment-form/

20/01/2026

If you haven't done so yet, make sure to register for the International Conference on Nuclear Cardiology ( ) to connect with experts and explore the latest innovations in .

📅 May 17-19, 2026
📍 Berlin, Germany
🤝 Co-organised by and the American Society of Nuclear Cardiology

Register here 👉 https://bit.ly/3LMgvAH

19/01/2026

Are you active on social media and want to make an impact? Join our EANM Social Media Ambassadors team! 🌍📲

We are looking to welcome up to two new ambassadors to join our dedicated and engaged group. You will help promote EANM’s events and projects and offer a behind the scenes look at .

📅 Application deadline: Monday, February 9, 2026

🔗 Check out the requirements and benefits and apply here: https://eanm.org/public-and-media-relations/social-media/

16/01/2026

SASAI is preparing for its next audit!

We invite you to share your interest and preferred products for a potential SASAI audit at Rotem. Every response matters, and your feedback will help us better serve the needs of our community.

Take the survey now 👉

SASAI - potential audit at Rotem in 2026